Literature DB >> 15905757

Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome.

Feriha Ozer1, Hasan Meral, Betul Aydin, Lutfu Hanoglu, Tuba Aydemir, Timucin Oral.   

Abstract

In the late-stage idiopathic Parkinson's disease (IDP), comorbid conditions such as depression and drug-induced psychosis may be observed. A patient with Parkinson disease, major depression, and paranoid psychosis who developed neuroleptic malignant syndrome (NMS) as the result of the sudden termination of high-dose (1200 mg/d) levodopa treatment is presented in this report. Because the patient did not respond to other treatment modalities, electroconvulsive therapy (ECT) was applied, and a rapid improvement was observed both in the patient's NMS and also in Parkinson's and psychiatric symptoms, with no additional side effects other than transient post-ictal confusions. The application of ECT allowed the patient to remain stable for a 5-year period with a quite low dose of levodopa (300 mg/d). Later, the patient had two episodes of depressive and psychotic symptoms, which were again successfully treated with the ECT. We suggest that ECT might be an effective and life-saving therapy in patients with severe, drug-resistant NMS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905757     DOI: 10.1097/01.yct.0000159325.08303.45

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  9 in total

Review 1.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 2.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 4.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

5.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03

6.  Bifrontal ECT for drug-induced psychosis in Parkinson's disease.

Authors:  K Muralidharan; R Thimmaiah; V Chakraborty; S Jain
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

7.  Propofol-remifentanil combination for management of electroconvulsive therapy in a patient with neuroleptic malignant syndrome.

Authors:  Modabber Arasteh; Shoaleh Shami; Karim Nasseri
Journal:  Case Rep Med       Date:  2012-04-03

8.  Successful Emergency Treatment of Refractory Neuroleptic Malignant Syndrome With Electroconvulsive Therapy and a Novel Use of Dexmedetomidine: A Case Report From California in the Era of COVID-19.

Authors:  Rajani Rajan; Mary Sage
Journal:  J ECT       Date:  2021-03-01       Impact factor: 3.692

9.  Afebrile Neuroleptic Malignant Syndrome associated with Fluphenazine decanoate: A case report.

Authors:  Marzieh Assareh; Laleh Koohi Habibi
Journal:  Iran J Psychiatry       Date:  2010
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.